Moderna reports EMA review of COVID-19 vaccine candidate, U.K. supply deal

By The Science Advisory Board staff writers

November 17, 2020 -- Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The company has also inked an agreement to supply the vaccine to the U.K. government.

As it continues its ongoing dialogue with the EMA, Moderna said it's also scaling up global manufacturing with its strategic partners Lonza of Switzerland and ROVI of Spain in order to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021.

In a related development, Moderna has also signed a deal to supply mRNA-1273 to the U.K. government. Supply would begin in March 2021 if the vaccine candidate is approved by the U.K. regulatory authorities. The Medicines and Healthcare products Regulatory Agency began its rolling review process of mRNA-1273 on October 27, Moderna said.

Moderna reports 94.5% efficacy for COVID-19 vaccine
A COVID-19 vaccine under development by Moderna had 94.5% efficacy in a phase III clinical trial, according to an independent data safety monitoring board...
Moderna finalizes interim results for COVID-19 vaccine
Moderna has completed case accrual for its first interim analysis of a phase III study of its COVID-19 vaccine candidate.
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...
Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate,...
Moderna secures $56M for mobile vaccine manufacturing
Moderna has received $56 million from the Defense Advanced Research Projects Agency to fund manufacturing of nucleic acid vaccines and therapeutics.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter